GSK (NYSE:GSK) & Clene (NASDAQ:CLNN) Critical Comparison

GSK (NYSE:GSK) and Clene (NASDAQ:CLNN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Institutional & Insider Ownership

15.7% of GSK shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares GSK and Clene”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07 billion	2.26	$7.54 billion	$3.20	15.04
Clene	$197,000.00	232.85	-$26.17 million	($3.50)	-1.02

GSK has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

GSK has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Profitability

This table compares GSK and Clene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Clene	-20,063.96%	N/A	-137.04%

Analyst Recommendations

This is a breakdown of recent ratings for GSK and Clene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2	7	0	1	2.00
Clene	1	0	6	0	2.71

GSK currently has a consensus target price of $53.00, indicating a potential upside of 10.11%. Clene has a consensus target price of $34.00, indicating a potential upside of 852.38%. Given Clene’s stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than GSK.

Summary

GSK beats Clene on 8 of the 15 factors compared between the two stocks.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.